Skip to main content
Erschienen in: Acta Neurologica Belgica 1/2017

27.12.2016 | Original Article

Impact of autonomic dysfunctions on the quality of life in Parkinson’s disease patients

verfasst von: Svetlana Tomic, Ines Rajkovaca, Vlasta Pekic, Tamer Salha, Sanja Misevic

Erschienen in: Acta Neurologica Belgica | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Autonomic dysfunctions are part of a spectrum of non-motor symptoms in Parkinson’s disease (PD) patients. The aim of the study was to assess the prevalence of autonomic dysfunctions and their influence on the quality of life (QoL) in PD patients, adjusted for age, sex, disease duration and motor symptoms. Patients were evaluated for motor function (Unified Parkinson’s Disease Rating Scale, UPDRS part III), disease stage (Hoehn and Yahr scale, H&Y scale), autonomic dysfunction (Scales for Outcomes in Parkinson’s disease, Autonomic, SCOPA-AUT) and QoL (Parkinson’s Disease Questionnaire-39, PDQ-39). Urinary, gastrointestinal and sexual autonomic dysfunctions were most frequently reported, while the most severe symptoms were reported for sexual and urinary systems. Age and motor symptoms did not correlate with autonomic dysfunction, while disease duration correlated with cardiovascular dysfunction. There were sex differences on the thermoregulation subscale. All types of autonomic dysfunction influenced QoL, mostly gastrointestinal and thermoregulatory dysfunctions, except for sexual one. Many aspects of QoL (activity of daily living, emotion, cognitive functions, communication and social support) except for stigma and mobility were affected by autonomic dysfunctions. Age, disease duration, sex and motor symptoms were not found to affect global QoL scores, but had detrimental effects on different PDQ-39 dimensions. Autonomic dysfunctions influence QoL in more aspects than motor symptoms, age, disease duration and sex. Patients tend to be more stigmatized with motor than non-motor symptoms.
Literatur
1.
Zurück zum Zitat Micieli G, Tosi P, Marcheselli S, Cavallini A (2003) Autonomic dysfunction in Parkinson’s disease. Neurol Sci 24(1):S32–S34CrossRefPubMed Micieli G, Tosi P, Marcheselli S, Cavallini A (2003) Autonomic dysfunction in Parkinson’s disease. Neurol Sci 24(1):S32–S34CrossRefPubMed
2.
Zurück zum Zitat Jost WH (2003) Autonomic dysfunctions in idiopathic Parkinson’s disease. J Neurol 250(1):i28–i30CrossRefPubMed Jost WH (2003) Autonomic dysfunctions in idiopathic Parkinson’s disease. J Neurol 250(1):i28–i30CrossRefPubMed
3.
Zurück zum Zitat Li K, Reichmann H, Ziemssen T (2015) Recognition and treatment of autonomic disturbances in Parkinson’s disease. Expert Rev Neurother 15(10):1189–1203CrossRefPubMed Li K, Reichmann H, Ziemssen T (2015) Recognition and treatment of autonomic disturbances in Parkinson’s disease. Expert Rev Neurother 15(10):1189–1203CrossRefPubMed
4.
Zurück zum Zitat Liepelt-Scarfone I, Pilotto A, Müller K, Bormann C, Gauss K, Wurster I, Streffer J, Berg D (2015) Autonomic dysfunction in subjects at high risk for Parkinson’s disease. J Neurol 262(12):2643–2652CrossRefPubMed Liepelt-Scarfone I, Pilotto A, Müller K, Bormann C, Gauss K, Wurster I, Streffer J, Berg D (2015) Autonomic dysfunction in subjects at high risk for Parkinson’s disease. J Neurol 262(12):2643–2652CrossRefPubMed
5.
Zurück zum Zitat van Uem JM, Marinus J, Canning C, van Lummel R, Dodel R, Liepelt-Scarfone I, Berg D, Morris ME, Maetzler W (2015) Health-related quality of life in patients with Parkinson’s—a systematic review based on the ICF model. Neurosci Biobehav Rev 61:26–34PubMed van Uem JM, Marinus J, Canning C, van Lummel R, Dodel R, Liepelt-Scarfone I, Berg D, Morris ME, Maetzler W (2015) Health-related quality of life in patients with Parkinson’s—a systematic review based on the ICF model. Neurosci Biobehav Rev 61:26–34PubMed
6.
Zurück zum Zitat Prakash KM, Nadkarni NV, Lye WK, Yong MH, Tan EK (2016) The impact of non-motor symptoms on the quality of life of Parkinson’s disease patients: a longitudinal study. Eur J Neurol 23(5):854–860CrossRefPubMed Prakash KM, Nadkarni NV, Lye WK, Yong MH, Tan EK (2016) The impact of non-motor symptoms on the quality of life of Parkinson’s disease patients: a longitudinal study. Eur J Neurol 23(5):854–860CrossRefPubMed
7.
Zurück zum Zitat Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184CrossRefPubMedPubMedCentral Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ (2004) Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord 19(11):1306–1312CrossRefPubMed Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ (2004) Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord 19(11):1306–1312CrossRefPubMed
9.
Zurück zum Zitat Hagell P, Nygren C (2007) The 39 item Parkinson’s Disease Questionnaire (PDQ-39) revisited: implications for evidence based medicine. J Neurol Neurosurg Psychiatry 78:1191–1198CrossRefPubMedPubMedCentral Hagell P, Nygren C (2007) The 39 item Parkinson’s Disease Questionnaire (PDQ-39) revisited: implications for evidence based medicine. J Neurol Neurosurg Psychiatry 78:1191–1198CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Gołab-Janowska M, Budzianowska A, Honczarenko K (2011) Autonomic disorders in Parkinson’s disease. Ann Acad Med Stetin 57(1):11–15PubMed Gołab-Janowska M, Budzianowska A, Honczarenko K (2011) Autonomic disorders in Parkinson’s disease. Ann Acad Med Stetin 57(1):11–15PubMed
11.
Zurück zum Zitat Sakakibara R, Shinotoh H, Uchiyama T et al (2001) Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci 92(1–2):76–85CrossRefPubMed Sakakibara R, Shinotoh H, Uchiyama T et al (2001) Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci 92(1–2):76–85CrossRefPubMed
12.
Zurück zum Zitat De Luka SR, Svetel M, Pekmezović T, Milovanović B, Kostić VS (2014) When do the symptoms of autonomic nervous system malfunction appear in patients with Parkinson’s disease? Vojnosanit Pregl 71(4):346–351CrossRefPubMed De Luka SR, Svetel M, Pekmezović T, Milovanović B, Kostić VS (2014) When do the symptoms of autonomic nervous system malfunction appear in patients with Parkinson’s disease? Vojnosanit Pregl 71(4):346–351CrossRefPubMed
13.
Zurück zum Zitat Goldstein DS (2014) Dysautonomia in Parkinson disease. Compr Physiol 4(2):805–826PubMed Goldstein DS (2014) Dysautonomia in Parkinson disease. Compr Physiol 4(2):805–826PubMed
14.
Zurück zum Zitat van Rooden SM, Verbaan D, Stijnen T, Marinus J, van Hilten JJ (2016) The influence of age and approaching death on the course of nondopaminergic symptoms in Parkinson’s disease. Parkinsonism Relat Disord 24:113–118CrossRefPubMed van Rooden SM, Verbaan D, Stijnen T, Marinus J, van Hilten JJ (2016) The influence of age and approaching death on the course of nondopaminergic symptoms in Parkinson’s disease. Parkinsonism Relat Disord 24:113–118CrossRefPubMed
15.
Zurück zum Zitat Chaudhuri KR, Healy DG, Schapira AH (2006) Nonmotor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5(3):235–245CrossRefPubMed Chaudhuri KR, Healy DG, Schapira AH (2006) Nonmotor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5(3):235–245CrossRefPubMed
16.
Zurück zum Zitat Gallagher DA, Lees A, Schrag A (2010) What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord 25(15):2493–2500CrossRefPubMed Gallagher DA, Lees A, Schrag A (2010) What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord 25(15):2493–2500CrossRefPubMed
17.
Zurück zum Zitat Merola A, Romagnolo A, Rosso M, Lopez-Castellanos JR, Wissel BD, Larkin S, Bernardini A, Zibetti M, Maule S, Lopiano L, Espay AJ (2016) Orthostatic hypotension in Parkinson’s disease: does it matter if asymptomatic? Parkinsonism Relat Disord 33:65–71CrossRefPubMed Merola A, Romagnolo A, Rosso M, Lopez-Castellanos JR, Wissel BD, Larkin S, Bernardini A, Zibetti M, Maule S, Lopiano L, Espay AJ (2016) Orthostatic hypotension in Parkinson’s disease: does it matter if asymptomatic? Parkinsonism Relat Disord 33:65–71CrossRefPubMed
18.
Zurück zum Zitat Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N (2003) Sweating dysfunctions in Parkinson’s disease. Mov Disord 18(12):1459–1463CrossRefPubMed Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N (2003) Sweating dysfunctions in Parkinson’s disease. Mov Disord 18(12):1459–1463CrossRefPubMed
19.
Zurück zum Zitat Hristova DR, Hristov JI, Mateva NG, Papathanasiou JV (2009) Quality of life in patients with Parkinson’s disease. Folia Med (Plovdiv) 51(4):58–64 Hristova DR, Hristov JI, Mateva NG, Papathanasiou JV (2009) Quality of life in patients with Parkinson’s disease. Folia Med (Plovdiv) 51(4):58–64
Metadaten
Titel
Impact of autonomic dysfunctions on the quality of life in Parkinson’s disease patients
verfasst von
Svetlana Tomic
Ines Rajkovaca
Vlasta Pekic
Tamer Salha
Sanja Misevic
Publikationsdatum
27.12.2016
Verlag
Springer International Publishing
Erschienen in
Acta Neurologica Belgica / Ausgabe 1/2017
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-016-0739-6

Weitere Artikel der Ausgabe 1/2017

Acta Neurologica Belgica 1/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.